… Topotecan is the only single-agent therapy approved by the US … treatment of patients with
recurrent small cell lung cancer (SCLC). Poor performance status (PS) at the time of relapse …

… treatment-free interval, and the patient's performance status. … an important treatment option
for these patients. This review … of single-agent topotecan in patients with recurrent SCLC and …

… in these patients. Previous data have demonstrated that topotecan provides improvement
even in patients with poor … In this analysis, we investigated whether treatment with topotecan is …

… in patients with relapsed SCLC and as first-line therapy in patients with poor performance
status.12, 13 In general this schedule was associated with relatively low severe hematologic …

… In most of the studies, patients with performance status of 1 and men were the majority.
Mean or median age presented for each study ranged from 58 to 68 years. Two studies did not …

… of the patients and thus single-agent therapy with topotecan is the standard treatment for
relapsed SCLC. … A total of 76.8% of patients had performance status ECOG 0-1. The majority of …

… A minimisation method with biased coin balancing was used for ECOG performance
status (0–1 vs 2), response to first-line chemotherapy (partial vs complete response), and …

… ; moreover, drug administration depends on individual factors, such as the extent of
metastatic disease, performance status (PS) score, laboratory parameters, and quality of life.7-9 …

… logic therapy, or surgery; (6) Zubrod performance status (PS) 2 and life expectancy 2 3
months; (7) hemoglobin level > 9.0 g/dL, WBC count greater than 4,000/jiL, granulocyte count 2 …

… Eligibility included the following: bidimensionally measurable disease, Eastern Cooperative
Oncology Group performance status of less than or equal to 2, and adequate marrow, liver, …